Sanofi’s tolebrutinib fails 2 of trio of phase 3 MS trials, but pharma still plans FDA filing

Sanofi’s tolebrutinib fails 2 of trio of phase 3 MS trials, but pharma still plans FDA filing jwaldron Sun, 09/01/2024 - 15:50